aibioXAIR Beyond Air, Inc.
Beyond Air (XAIR) news
Beyond Air, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker XAIR, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest Beyond Air news
We have not published a story on Beyond Air yet. When there is news, it will appear here.
What Beyond Air does
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide generators and delivery systems called LungFit, which generates nitric oxide from ambient air. Its first device, LungFit PH, received FDA premarket approval in June 2022 to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in neonates with hypoxic respiratory failure associated with pulmonary hypertension, known as persistent pulmonary hypertension of the newborn. In November 2024 the company received CE mark approval for LungFit PH in the European Union. The company says it has regulatory approvals in more than 27 other countries and distribution agreements covering over 40 countries outside the United States. Other areas of focus include nontuberculous mycobacteria lung infections and severe lung infections with underlying chronic obstructive pulmonary disease. Beyond Air holds 80% of Beyond Cancer, Ltd., which is developing an ultra-high concentration nitric oxide delivery system for solid tumors, a program that recently completed a Phase 1 human clinical trial. It also holds 84.75% of NeuroNOS Limited, which is developing nNOS inhibitors, with autism spectrum disorder as the first target indication.
| Product or program | What it is | Stage |
|---|---|---|
| LungFit PH | Nitric oxide generator for neonates with hypoxic respiratory failure and pulmonary hypertension | FDA premarket approval (June 2022); CE marked (November 2024) |
| LungFit platform for lung infections | Nitric oxide delivery for nontuberculous mycobacteria and severe lung infections with COPD | |
| Ultra-high concentration nitric oxide delivery system | Delivers nitric oxide above 10,000 ppm directly to solid tumors | Phase 1 human clinical trial recently completed |
| nNOS inhibitors | Partial inhibitors of neuronal nitric oxide synthase; first target autism spectrum disorder |
Beyond Air annual financials
| Line | FY ended Mar 31, 2026 | FY ended Mar 31, 2025 |
|---|---|---|
| Revenue | $7.7 million | $3.7 million |
| Research and development | $10.2 million | $16.9 million |
| Net income (loss) | -$33.2 million | -$46.6 million |
| Cash from operations | -$18.1 million | -$38.2 million |
| Cash and equivalents | $6.7 million | $4.7 million |
| Short-term investments | $4.9 million | $2.3 million |
Questions about Beyond Air
What is the ticker symbol of Beyond Air?
Beyond Air, Inc. trades under the ticker XAIR on NASDAQ.
Where is Beyond Air listed?
Beyond Air, Inc. is listed on NASDAQ.
Which country or territory is Beyond Air listed under?
Our directory records Beyond Air, Inc. under United States.
Does aibio.space cover Beyond Air?
aibio.space lists Beyond Air, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
What does Beyond Air develop?
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide generators and delivery systems called LungFit, which generates nitric oxide from ambient air. Its first device, LungFit PH, received FDA premarket approval in June 2022 to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in neonates with hypoxic respiratory failure associated with pulmonary hypertension, known as persistent pulmonary hypertension of the newborn.
What is LungFit PH from Beyond Air?
LungFit PH: Nitric oxide generator for neonates with hypoxic respiratory failure and pulmonary hypertension Stage: FDA premarket approval (June 2022); CE marked (November 2024).
What is LungFit platform for lung infections from Beyond Air?
LungFit platform for lung infections: Nitric oxide delivery for nontuberculous mycobacteria and severe lung infections with COPD Stage: Stage not stated.
What was Beyond Air's revenue last year?
$7.7 million for the fiscal year ended Mar 31, 2026, as reported to the SEC.
Is Beyond Air profitable?
Beyond Air, Inc. reported a net loss of $33.2 million for the fiscal year ended Mar 31, 2026, and used $18.1 million of cash in operations, per its annual report to the SEC.
How much does Beyond Air spend on research and development?
$10.2 million in the fiscal year ended Mar 31, 2026, per its annual report.
How much cash does Beyond Air have?
$9.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Investor discussion: Beyond Air
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
- Listings
Reported a reverse stock split. SEC Form 8-K (Items 2.02,5.03,7.01,9.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
- Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Stock chart
Listing details
- Company
- Beyond Air, Inc.
- Ticker
- XAIR
- Listing
- NASDAQ
- Country or territory
- United States
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction